title: ACPA and bone loss in rheumatoid arthritis.
abstract: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease characterized by bone loss. Degree of inflammation and autoantibody positivity have both been identified as important initiators of skeletal damage in RA. Whereas it is well appreciated that inflammation initiates bone loss via the action of cytokines, the effect of autoantibodies in initiating bone destruction has long been underestimated. It has, nonetheless, been known for years that antibodies against citrullinated proteins (ACPA) and rheumatoid factor are associated with a more destructive disease course. It was recently shown that ACPA bind osteoclast precursor cells and directly promote their differentiation into bone-resorbing osteoclasts. Other results have shown that in ACPA-positive individuals bone loss starts even before the onset of clinical disease; this is indicative of the independent effect of these antibodies in initiating skeletal damage. The observation that the mere presence of ACPA is associated with pathological changes suggests that these antibodies have functional properties and initiate the onset of disease long before patients consult the rheumatologist because of symptomatic joint disease. These findings also indicate that "RA" is a syndrome rather than a single disease, suggesting that autoantibody-positive patients are both genetically and clinically distinct phenotypes.
authors: Department of Internal Medicine 3 and Institute of Clinical Immunology, University of Erlangen-Nuremberg, 91054, Erlangen, Germany.
authors: Roland
authors: R
authors: Kocijan
authors: Ulrike
authors: U
authors: Harre
authors: Georg
authors: G
authors: Schett
mesh_terms: D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000473:pathology; D001323:Autoantibodies / Q000276:immunology*; D001842:Bone and Bones / Q000473:pathology*; D002956:Citrulline / Q000276:immunology; D006801:Humans; D010456:Peptides, Cyclic / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D010456:Peptides, Cyclic; D002956:Citrulline
references: Arthritis Rheum. 2010 Feb;62(2):330-9
references: 20112404
references: Ann Rheum Dis. 2006 Apr;65(4):535-7
references: 16079166
references: Ann Rheum Dis. 2003 May;62(5):427-30
references: 12695154
references: Ann Rheum Dis. 2013 Jun;72(6):901-7
references: 22915618
references: Arthritis Res Ther. 2010;12(3):R96
references: 20482894
references: Curr Rheumatol Rep. 2011 Jun;13(3):241-50
references: 21369797
references: J Clin Invest. 2012 May;122(5):1791-802
references: 22505457
references: Ann Rheum Dis. 2012 May;71(5):638-41
references: 22387728
references: Rheumatology (Oxford). 2012 Jun;51(6):1037-41
references: 22258391
references: Arthritis Rheum. 2006 Jan;54(1):38-46
references: 16385494
references: Arthritis Rheum. 2000 Aug;43(8):1831-5
references: 10943873
references: Arthritis Res Ther. 2009;11(4):R103
references: 19570223
references: Ann Rheum Dis. 2010 Sep;69(9):1580-8
references: 20699241
references: Rheumatol Int. 2013 Feb;33(2):451-6
references: 22457007
references: Ann Rheum Dis. 2010 Feb;69(2):345-51
references: 19648126
references: N Engl J Med. 2011 Dec 8;365(23):2205-19
references: 22150039
references: Scand J Rheumatol. 2008 Sep-Oct;37(5):337-42
references: 18609264
references: Ann Rheum Dis. 2010 Jun;69(6):1110-6
references: 20439289
references: Arthritis Rheum. 2003 Oct;48(10):2741-9
references: 14558078
references: Nat Rev Rheumatol. 2012 Nov;8(11):656-64
references: 23007741
references: Ann Rheum Dis. 2011 Jun;70(6):1173-4
references: 20956407
references: Ann Rheum Dis. 2009 Mar;68(3):330-6
references: 18375540
references: Clin Exp Rheumatol. 2011 May-Jun;29(3):500-5
references: 21640044
references: Ann Rheum Dis. 2010 Oct;69(10):1789-95
references: 20444751
references: Ann Rheum Dis. 2010 Aug;69(8):1554-61
references: 20448290
references: J Bone Miner Res. 2009 Jul;24(7):1142-6
references: 19557892